Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAmbetter Nevada Akeega Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedAmbetter NevadaPolicy CP.PHAR.645

    Clinical Policy: Niraparib/Abiraterone Acetate (Akeega)

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.PHAR.645 alerts

    Get alerted when Policy CP.PHAR.645 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for niraparib/abiraterone acetate (Akeega) in adults with specified metastatic prostate cancer indications across commercial, HIM/ICHRA, and Medicaid lines of business in Nevada.

    Policy Summary
    PayerAmbetter Nevada
    PolicyNiraparib/Abiraterone Acetate (Akeega)
    Policy CodePolicy CP.PHAR.645
    Change TypeModified
    Effective DateDec 1, 2023
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation confirming the covered metastatic prostate cancer diagnosis, qualifying BRCA mutation, prednisone use, and required androgen-deprivation therapy.
    SourceLink
    POLICY UPDATE CHANGES

    The policy removed coverage for the previously described off-label use involving disease progression despite bilateral orchiectomy or other androgen deprivation therapy.

    The initial approval duration was extended from 6 months to 12 months for Medicaid and HIM members.

    A new indication for BRCA2-mutated metastatic castration-sensitive prostate cancer was added.

    The ICHRA line of business was added to the policy.

    2FDA-approved prostate cancer indications
    ≥18 yearsMinimum age
    2 tablets/dayMaximum daily dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 months
    Approval duration
    No prior PARP inhibitorInitial therapy requirement
    BRCA2-mutated mCSPCNew indication

    Coverage Criteria

    Initial therapy

    Covered for prostate cancer when ALL of the following are met:

    Initial therapy criteria

    • Clinical and treatment requirements

      • Qualifying diagnosis

        • Member has a diagnosis of metastatic castration-resistant prostate cancer (mCRPC).
        • Member has a diagnosis of metastatic castration-sensitive prostate cancer (mCSPC).
      • The drug is prescribed by or in consultation with an oncologist or urologist.
      • Member is at least 18 years old.≥18 years
      • Akeega is prescribed in combination with prednisone.
      • For brand Akeega requests, the member uses generic niraparib/abiraterone acetate when available, unless generic use is contraindicated or causes clinically significant adverse effects.
      • Androgen-deprivation status

        • Therapy is prescribed concurrently with a gonadotropin-releasing hormone (GnRH) analog.
        • The member has had a bilateral orchiectomy.
      • Member has not previously received a PARP inhibitor, including Lynparza, Rubraca, Talzenna, or Zejula.
    • Qualifying BRCA mutation by disease state

      • For mCRPC: a BRCA1 or BRCA2 mutation is documented.
      • For mCSPC: a BRCA2 mutation is documented.
    • Qualifying dose

      • The requested dose does not exceed 200 mg niraparib/1,000 mg abiraterone acetate per day and does not exceed 2 tablets per day.200 mg niraparib/1,000 mg abiraterone acetate daily; maximum 2 tablets daily
      • The requested dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, with supporting evidence submitted by the prescriber.

        The prescribed regimen must be FDA-approved or recommended by NCCN.

    Dose criteria

    The requested regimen or dose must meet ONE of the following pathways:

    Dose requirement

    • Standard dose pathway: The dose does not exceed both of the following limits: 200 mg niraparib/1,000 mg abiraterone acetate per day and 2 tablets per day.200 mg niraparib/1,000 mg abiraterone acetate daily; maximum 2 tablets daily
    • Supported off-label dose pathway: The dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, and the prescriber submits supporting evidence.

      The prescribed regimen must be FDA-approved or recommended by NCCN.

    Continuation therapy

    Covered continuation therapy requires ALL of the following:

    Continuation criteria

    • Current therapy documentation

      • The member is currently receiving the medication through the Centene benefit.
      • Documentation supports that the member is currently receiving Akeega for a covered indication and has received it for at least 30 days.At least 30 days
    • The member is responding positively to therapy.
    • For brand Akeega requests, the member uses generic niraparib/abiraterone acetate when available, unless generic use is contraindicated or causes clinically significant adverse effects.

    Other diagnoses and indications

    Other diagnoses or indications must meet ONE of the following pathways:

    Other indication pathway

    • Recent label-change pathway: If the drug has undergone a label change within the last 6 months that is not yet reflected in this policy, refer to the applicable no-coverage-criteria or non-formulary policy based on formulary or PDL status and line of business.Label change within the last 6 months

      For commercial, HIM/ICHRA, or Medicaid members, use the applicable line-of-business policy.

    • Off-label pathway: If the requested use is not specifically listed under the diagnoses or indications for which coverage is not authorized, and the recent-label-change pathway does not apply, refer to the applicable off-label use policy for the member’s line of business.

      Use the applicable commercial, HIM/ICHRA, or Medicaid off-label policy.

    Non-FDA-approved indications not addressed by this policy are not authorized. Coverage may be considered only when sufficient documentation of efficacy and safety supports review under the applicable off-label use policy: CP.CPA.09 for commercial members, HIM.PA.154 for health insurance marketplace/ICHRA members, or CP.PMN.53 for Medicaid members, or under the applicable evidence of coverage documents.

    Clinical Thresholds and Coding Information

    Castrate Serum Testosterone
    Testosterone threshold< 50 ng/dL
    MeasurementSerum testosterone
    Clinical useDefines castrate levels of serum testosterone

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Clinical Authorization

    Submit an initial authorization request for Akeega for an adult member with metastatic castration-resistant prostate cancer (mCRPC) or metastatic castration-sensitive prostate cancer (mCSPC). The prescription must be written by, or in consultation with, an oncologist or urologist, and documentation supporting all approval criteria is required.

    • Member must be age ≥ 18 years.
    • Submit office chart notes, laboratory results, or other clinical information supporting that all approval criteria are met.
    Prior Authorization

    Dose Authorization

    For initial requests and dose increases, the requested regimen must not exceed the standard maximum unless an exception is substantiated. A nonstandard dose requires supporting practice guidelines or peer-reviewed literature for the relevant off-label use.

    • Standard maximum: 200 mg niraparib/1,000 mg abiraterone acetate per day.
    • Standard maximum: 2 tablets per day.

    Therapy Background

    Akeega combines the PARP inhibitor niraparib with the CYP17 inhibitor abiraterone acetate and is administered with prednisone. Its covered use is molecularly selected for adults with deleterious or suspected deleterious BRCA-mutated metastatic prostate cancer: BRCA1 or BRCA2 mutations in metastatic castration-resistant prostate cancer (mCRPC), and BRCA2 mutations in metastatic castration-sensitive prostate cancer (mCSPC).

    For mCRPC, androgen deprivation must continue with a GnRH/LHRH agent or follow prior bilateral orchiectomy.

    Definitions and Abbreviations

    mCRPC
    AbbreviationmCRPC
    Full termMetastatic castration-resistant prostate cancer
    Disease categoryProstate cancer with metastatic, castration-resistant disease
    mCSPC
    AbbreviationmCSPC
    Full termMetastatic castration-sensitive prostate cancer
    Disease categoryProstate cancer with metastatic, castration-sensitive disease

    Initial Prostate Cancer Therapy

    Initial prostate cancer therapy

    Initial therapy requires ALL of the following prostate cancer criteria and ONE qualifying dose pathway:

    Initial Akeega therapy

    • Qualifying diagnosis

      • Member has metastatic castration-resistant prostate cancer (mCRPC).
      • Member has metastatic castration-sensitive prostate cancer (mCSPC).
    • Akeega is prescribed by or in consultation with an oncologist or urologist.
    • Member is at least 18 years old.≥18 years

    Continuation Therapy

    Continuation therapy

    Continuation therapy must meet ALL of the following:

    Continuation criteria

    • Current therapy documentation

      • Current therapy is documented through the Centene benefit.
      • The member is currently receiving Akeega for a covered indication and has received the medication for at least 30 days.At least 30 days
    • The member is responding positively to therapy.
    • For brand Akeega requests, the member uses generic niraparib/abiraterone acetate when available, unless generic use is contraindicated or causes clinically significant adverse effects.

    Generic-First Requirement

    StepRequirementException
    1
    Use generic niraparib/abiraterone acetate before brand Akeega when the generic is available.
    Brand Akeega may be used without this step when generic use is contraindicated or causes clinically significant adverse effects.

    Dose and Quantity Limits

    Quantity Limit
    MedicationAkeega or generic niraparib/abiraterone acetate
    Quantity limit2 tablets
    Limit perDay
    Maximum Daily Strength
    MedicationNiraparib/abiraterone acetate
    Maximum niraparib strength200 mg per day
    Maximum abiraterone acetate strength1,000 mg per day
    Policy Summary
    PayerAmbetter Nevada
    PolicyNiraparib/Abiraterone Acetate (Akeega)
    Policy CodePolicy CP.PHAR.645
    Change TypeModified
    Effective DateDec 1, 2023
    Last ReviewNov 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation confirming the covered metastatic prostate cancer diagnosis, qualifying BRCA mutation, prednisone use, and required androgen-deprivation therapy.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Coding InformationAuthorization and Documentation RequirementsTherapy BackgroundDefinitions and AbbreviationsInitial Prostate Cancer TherapyContinuation TherapyGeneric-First RequirementDose and Quantity Limits

    Dose-increase requirement

    • The new dose does not exceed both of the following limits: 200 mg niraparib/1,000 mg abiraterone acetate per day and 2 tablets per day.200 mg niraparib/1,000 mg abiraterone acetate daily; maximum 2 tablets daily
    • The new dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, and the prescriber submits supporting evidence.

      The prescribed regimen must be FDA-approved or recommended by NCCN.

  1. The prescribed regimen must be FDA-approved or recommended by NCCN.
  2. Prior Authorization

    Continuation Authorization

    For continuation authorization, document that the member is currently receiving Akeega through the Centene benefit, or is currently receiving Akeega for a covered indication, and has received it for at least 30 days. Also document that the member is responding positively to therapy.

    • Continuation criteria must be met for all covered prostate cancer requests.
    • Dose-increase requests must meet the standard maximum or nonstandard-dose evidence requirement.
    Step Therapy

    Generic Substitution Required

    For brand Akeega requests, the member must use generic niraparib/abiraterone acetate when available. An exception requires documentation that the generic is contraindicated or caused clinically significant adverse effects.

    • This requirement applies to both initial and continued-therapy brand requests.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Denial Risk

    Failure to Meet Clinical Criteria

    Coverage may be denied when required clinical criteria are not met or cannot be documented, including the covered diagnosis, qualifying mutation, appropriate prescriber, prednisone combination, androgen-deprivation therapy or bilateral orchiectomy, and applicable treatment-history requirements.

    • Covered diagnosis must be mCRPC or mCSPC.
    • Prescriber must be or consult with an oncologist or urologist, and the member must be age ≥ 18 years.
    • Required mutation: BRCA1 or BRCA2 for mCRPC, or BRCA2 for mCSPC, confirmed by a CLIA-approved diagnostic test.
    • Akeega must be prescribed with prednisone and concurrently with a GnRH analog, unless the member has had a bilateral orchiectomy.
    • Initial approval is not authorized after prior PARP inhibitor therapy.
    • Dose requests must meet the standard maximum or include supporting practice guidelines or peer-reviewed literature for the relevant off-label use.
    CRPC
    AbbreviationCRPC
    DefinitionProstate cancer that progresses clinically, radiographically, or biochemically despite castrate serum testosterone levels
    Castrate testosterone threshold< 50 ng/dL
    PARP
    AbbreviationPARP
    Full termPoly (ADP-ribose) polymerase
    Policy terminologyPARP inhibitor
    GnRH
    AbbreviationGnRH
    Full termGonadotropin-releasing hormone
    Related terminologyLHRH: luteinizing hormone-releasing hormone
    CLIA
    AbbreviationCLIA
    Full termClinical Laboratory Improvement Amendments
    Documentation terminologyCLIA-approved diagnostic test
  3. Qualifying BRCA mutation

    • For mCRPC, a BRCA1 or BRCA2 mutation is documented.
    • For mCSPC, a BRCA2 mutation is documented.
  4. Akeega is prescribed in combination with prednisone.
  5. For brand Akeega requests, the member uses generic niraparib/abiraterone acetate when available, unless generic use is contraindicated or causes clinically significant adverse effects.
  6. Androgen-deprivation status

    • Therapy is prescribed concurrently with a GnRH analog.
    • The member has had a bilateral orchiectomy.
  7. Member has not previously received a PARP inhibitor, including Lynparza, Rubraca, Talzenna, or Zejula.
  8. Qualifying dose

    • The requested dose does not exceed 200 mg niraparib/1,000 mg abiraterone acetate per day and 2 tablets per day.200 mg niraparib/1,000 mg abiraterone acetate daily; maximum 2 tablets daily
    • The requested dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, with supporting evidence submitted by the prescriber.

      The prescribed regimen must be FDA-approved or recommended by NCCN.

  9. Dose-increase requirement

    • The new dose does not exceed 200 mg niraparib/1,000 mg abiraterone acetate per day and 2 tablets per day.200 mg niraparib/1,000 mg abiraterone acetate daily; maximum 2 tablets daily
    • The new dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, with supporting evidence submitted by the prescriber.

      The prescribed regimen must be FDA-approved or recommended by NCCN.